Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research
Authors:
- Fabio ConfortiFCFabio Conforti
- Laura PalaLPLaura Pala
- Tommaso De PasTommaso De Pas
- Emma ZattarinEZEmma Zattarin
- Chiara CataniaCCChiara Catania
- Emilia CocorocchioECEmilia Cocorocchio
- Giovanna RossiGRGiovanna Rossi
- Daniele LaszloDLDaniele Laszlo
- Marco ColleoniMCMarco Colleoni
- Alberto ZambelliAZAlberto Zambelli
- Gabriel N. HortobagyiGHGabriel N. Hortobagyi
- Javier CortesJavier Cortes
- 31 October 2023
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (6) , 1093-1103
Abstract
After decades of research, improving the efficacy of adjuvant endocrine therapy (ET) for early-stage breast cancer becomes increasingly difficult. Beyond technological breakthroughs and the availability of new classes of drugs, further improvement of adjuvant ET will require applying a rigorous research approach in poorly investigated areas. We critically discuss some key principles that should inform future research to improve ET efficacy, including identifying specific subgroups of patients who can benefit from escalating or de-escalating approaches, optimizing available and new treatment strategies for different clinical contexts, and dissecting the direct and indirect biological effects of therapeutic interventions. Four main issues regarding adjuvant ET were identified as relevant areas, where a better application of such principles can provide positive results in the near future: (i) tailoring the optimal duration of adjuvant ET, (ii) optimizing ovarian function suppression for premenopausal women, (iii) dissecting the biological effects of estrogen receptor manipulation, and (iv) refining the selection of patients to candidate for treatments escalation.Keywords
This publication has 67 references indexed in Scilit:
- Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer. A systematic review and meta-analysis of randomized clinical trialsThe Breast, 2023
- Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancerAnnals of Oncology, 2022
- 133O Extended adjuvant aromatase inhibition after sequential endocrine therapy: Final results of the phase III DATA trialAnnals of Oncology, 2022
- Sex and cancer immunotherapy: Current understanding and challengesCancer Cell, 2022
- Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021Annals of Oncology, 2021
- Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibitionCell, 2021
- Assessment of Molecular Relapse Detection in Early-Stage Breast CancerJAMA Oncology, 2019
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trialThe Lancet, 2013
- Lower-Dose vs High-Dose Oral Estradiol Therapy of Hormone Receptor–Positive, Aromatase Inhibitor–Resistant Advanced Breast CancerJAMA, 2009
- Survival patterns after oophorectomy in premenopausal women: a population-based cohort studyThe Lancet Oncology, 2006